Posted on

Cdc cbd oil for blood pressure

Cannabidiol (CBD)

Cannabidiol (CBD) is a chemical in the Cannabis sativa plant, also known as cannabis or hemp. One specific form of CBD is approved as a drug in the U.S. for seizure.

Over 80 chemicals, known as cannabinoids, have been found in the Cannabis sativa plant. Delta-9-tetrahydrocannabinol (THC) is the most famous ingredient in cannabis. But CBD is obtained from hemp, a form of the Cannabis sativa plant that only contains small amounts of THC. CBD seems to have effects on some chemicals in the brain, but these are different than the effects of THC.

A prescription form of CBD is used for seizure disorder (epilepsy). CBD is also used for anxiety, pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions, but there is no good scientific evidence to support these uses.

Laws passed in 2018 made it legal to sell hemp and hemp products in the US. But that doesn’t mean that all CBD products made from hemp are legal. Since CBD is an approved prescription drug, it can’t be legally included in foods or dietary supplements. CBD can only be included in “cosmetic” products. But there are still CBD products on the market that are labeled as dietary supplements. The amount of CBD contained in these products is not always the same as what is stated on the label.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for CANNABIDIOL (CBD) are as follows:

Likely effective for.

  • Seizure disorder (epilepsy). A specific prescription product (Epidiolex, GW Pharmaceuticals) is approved by the US FDA to treat seizures caused by Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex. It is unclear if other forms of CBD are helpful for seizure. For now, stick with the prescription product.

Is it safe?

When taken by mouth: CBD is possibly safe to take in appropriate doses. Doses of up to 200 mg daily have been used safely for up to 13 weeks. With the guidance of a healthcare provider, a specific prescription CBD product (Epidiolex) has been used at higher doses and for longer durations.

CBD can cause some side effects, such as dry mouth, low blood pressure, light headedness, and drowsiness. Signs of liver injury have also been reported with high doses of the prescription form of CBD, called Epidiolex.

When applied to the skin: There isn’t enough reliable information to know if CBD is safe or what the side effects might be.

Special precautions & warnings:

Pregnancy and breast-feeding: It may be unsafe to take CBD if you are pregnant or breast feeding. CBD products can be contaminated with other ingredients that may be harmful to the fetus or infant. Stay on the safe side and avoid use.

Children: It is possibly safe for children to take a specific prescription CBD product (Epidiolex) by mouth in doses up to 25 mg/kg daily. This product is approved for use in children with certain conditions who are at least 1 year old. It isn’t clear if other CBD products are safe in children.

Liver disease: People with liver disease may need to use lower doses of CBD.

Parkinson disease: Some early research suggests that taking high doses of CBD might make muscle movement and tremors worse in some people with Parkinson disease.

Are there interactions with medications?

Moderate Be cautious with this combination. Brivaracetam (Briviact) Brivaracetam is changed and broken down by the body. CBD might decrease how quickly the body breaks down brivaracetam. This might increase levels of brivaracetam in the body. Caffeine Caffeine is changed and broken down by the body. CBD might decrease how quickly the body breaks down caffeine. This might increase levels of caffeine in the body. Carbamazepine (Tegretol) Carbamazepine is changed and broken down by the body. CBD might decrease how quickly the body breaks down carbamazepine. This might increase levels of carbamazepine in the body and increase its side effects. Citalopram (Celexa) Citalopram is changed and broken down by the body. CBD might decrease how quickly the body breaks down citalopram. This might increase levels of citalopram in the body and increase its side effects. Clobazam (Onfi) Clobazam is changed and broken down by the liver. CBD might decrease how quickly the liver breaks down clobazam. This might increase the effects and side effects of clobazam. Eslicarbazepine (Aptiom) Eslicarbazepine is changed and broken down by the body. CBD might decrease how quickly the body breaks down eslicarbazepine. This might increase levels of eslicarbazepine in the body by a small amount. Everolimus (Zostress) Everolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down everolimus. This might increase levels of everolimus in the body. Lithium Taking higher doses of CBD might increase levels of lithium. This can increase the risk of lithium toxicity. Medications changed by the liver (Cytochrome P450 1A1 (CYP1A1) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 1B1 (CYP1B1) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2A6 (CYP2A6) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2B6 (CYP2B6) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications changed by the liver (Glucuronidated drugs) Some medications are changed and broken down by the liver. CBD might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications. Medications that decrease the breakdown of other medications by the liver (Cytochrome P450 2C19 (CYP2C19) inhibitors) CBD is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD. Medications that decrease the breakdown of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) CBD is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD. Medications that increase breakdown of other medications by the liver (Cytochrome P450 3A4 (CYP3A4) inducers) CBD is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD. Medications that increase the breakdown of other medications by the liver (Cytochrome P450 2C19 (CYP2C19) inducers) CBD is changed and broken down by the liver. Some drugs increase how quickly the liver changes and breaks down CBD. This could change the effects and side effects of CBD. Methadone (Dolophine) Methadone is broken down by the liver. CBD might decrease how quickly the liver breaks down methadone. Taking cannabidiol along with methadone might increase the effects and side effects of methadone. Rufinamide (Banzel) Rufinamide is changed and broken down by the body. CBD might decrease how quickly the body breaks down rufinamide. This might increase levels of rufinamide in the body by a small amount. Sedative medications (CNS depressants) CBD might cause sleepiness and slowed breathing. Some medications, called sedatives, can also cause sleepiness and slowed breathing. Taking CBD with sedative medications might cause breathing problems and/or too much sleepiness. Sirolimus (Rapamune) Sirolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down sirolimus. This might increase levels of sirolimus in the body. Stiripentol (Diacomit) Stiripentol is changed and broken down by the body. CBD might decrease how quickly the body breaks down stiripentol. This might increase levels of stiripentol in the body and increase its side effects. Tacrolimus (Prograf) Tacrolimus is changed and broken down by the body. CBD might decrease how quickly the body breaks down tacrolimus. This might increase levels of tacrolimus in the body. Tamoxifen (Soltamox) Tamoxifen is changed and broken down by the body. CBD might affect how quickly the body breaks down tamoxifen. This might affect levels of tamoxifen in the body. Topiramate (Topamax) Topiramate is changed and broken down by the body. CBD might decrease how quickly the body breaks down topiramate. This might increase levels of topiramate in the body by a small amount. Valproate Valproic acid can cause liver injury. Taking cannabidiol with valproic acid might increase the chance of liver injury. CBD and/or valproic acid might need to be stopped, or the dose might need to be reduced. Warfarin CBD might increase levels of warfarin, which can increase the risk for bleeding. CBD and/or warfarin might need to be stopped, or the dose might need to be reduced. Zonisamide Zonisamide is changed and broken down by the body. CBD might decrease how quickly the body breaks down zonisamide. This might increase levels of zonisamide in the body by a small amount.

Are there interactions with herbs and supplements?

Herbs and supplements with sedative properties CBD might cause sleepiness and slowed breathing. Taking it along with other supplements with similar effects might cause too much sleepiness and/or slowed breathing in some people. Examples of supplements with this effect include hops, kava, L-tryptophan, melatonin, and valerian.

Are there interactions with foods?

CBD can be taken with food or without food. But taking it with food can cause the body to absorb more CBD than when it is taken without food. This might increase the effects of CBD.

Fatty foods or drinks, such as whole milk, and alcohol can also make the body absorb more CBD.

How is it typically used?

CBD has most often been used by adults in doses of 200 mg or less per day. Speak with a healthcare provider to find out what dose might be best for a specific condition.

For information on using prescription CBD, a product called Epidiolex, speak with a healthcare provider.

Other names

Methodology

To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.

References

  1. Carvalho RK, Rocha TL, Fernandes FH, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Interact 2022;351:109743. View abstract.
  2. Harris HM, Gul W, ElSohly MA, Sufka KJ. Differential Effects of Cannabidiol and a Novel Cannabidiol Analog on Oxycodone Place Preference and Analgesia in Mice: an Opioid Abuse Deterrent with Analgesic Properties. Cannabis Cannabinoid Res 2021. View abstract.
  3. Sepulveda DE, Morris DP, Raup-Konsavage WM, Sun D, Vrana KE, Graziane NM. Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice. Cannabis Cannabinoid Res 2021. View abstract.
  4. Kaufmann R, Aqua K, Lombardo J, Lee M. Observed Impact of Long-term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. Cannabis Cannabinoid Res 2021. View abstract.
  5. Jones É, Vlachou S. Cannabidiol Does Not Cause Significant Changes to Working Memory Performance in the N-Back Task. Pharmaceuticals (Basel) 2021;14:1165. View abstract.
  6. Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology (Berl) 2022. View abstract.
  7. Nguyen LC, Yang D, Nicolaescu V, et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv 2022. View abstract.
  8. Köck P, Lang E, Trulley VN, et al. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study. Front Psychiatry 2021;12:736822. View abstract.
  9. Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res 2021. View abstract.
  10. Klotz KA, Grob D, Schönberger J, et al. Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study. CNS Drugs 2021;35:1207-1215. View abstract.
  11. Baranowska-Kuczko M, Kozlowska H, Kloza M, et al. Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension. Pharmaceuticals (Basel) 2021;14:1120. View abstract.
  12. Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice. Pharmaceuticals (Basel) 2021;14:863. View abstract.
  13. Thiele EA, Bebin EM, Filloux F, et al. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia 2021. View abstract.
  14. Hotz J, Fehlmann B, Papassotiropoulos A, de Quervain DJ, Schicktanz NS. Cannabidiol enhances verbal episodic memory in healthy young participants: A randomized clinical trial. J Psychiatr Res 2021;143:327-333. View abstract.
  15. Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos 2021;49:1070-1080. View abstract.
  16. Davis BH, Beasley TM, Amaral M, et al. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clin Pharmacol Ther 2021;110:1368-1380. View abstract.
  17. Partridge Snow & Hahn LLP. FDA Refuses to Approve CBVD As a Food Ingredient or Supplement. August 19, 2021. Available at: https://www.jdsupra.com/legalnews/fda-refuses-to-approve-cbd-as-a-food-1880558. Accessed October 26, 2021.
  18. Masterson D. CBD from orange peels: A different CBD story. August 3, 2021. Available at: https://www.nutraingredients-usa.com/Article/2021/08/03/CBD-from-orange-peels-A-different-CBD-story?utm_source=newsletter_daily&utm_medium=email&utm_campaign=03-Aug-2021&cid=DM973784&bid=1668435211. Accessed October 26, 2021.
  19. Yu JS, Premkumar A, Liu S, Sculco P. Rates of self-directed perioperative cannabidiol use in patients undergoing total hip or knee arthroplasty. Pain Manag 2021;11:655-660. View abstract.
  20. Vela J, Dreyer L, Petersen KK, Lars AN, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. Pain 2021. View abstract.
  21. Isenmann E, Veit S, Starke L, Flenker U, Diel P. Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training. Nutrients 2021;13:3028. View abstract.
  22. Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62:2505-2517. View abstract.
  23. Madan Cohen J, Checketts D, Dunayevich E, et al. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Epilepsia 2021;62:2218-2227. View abstract.
  24. Patel AD, Mazurkiewicz-Beldzinska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia 2021;62:2228-2239. View abstract.
  25. Scheffer IE, Hulihan J, Messenheimer J, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open 2021;4:e2123930. View abstract.
  26. Devinsky O, Kraft K, Rusch L, Fein M, Leone-Bay A. Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study. J Pharm Sci 2021. View abstract.
  27. Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11:8951. View abstract.
  28. Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4:e2120603. View abstract.
  29. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. The dose-dependent analgesic effects, abuse liability, safety and tolerability of oral cannabidiol in healthy humans. Br J Clin Pharmacol. 2021. View abstract.
  30. Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18:e1003524. View abstract.
  31. van Orten-Luiten AB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2021. View abstract.
  32. Thai C, Tayo B, Critchley D. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Clin Pharmacol Drug Dev. 2021. View abstract.
  33. Spinella TC, Stewart SH, Naugler J, Yakovenko I, Barrett SP. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology (Berl). 2021. View abstract.
  34. Schneider T, Zurbriggen L, Dieterle M, et al. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). Pain. 2021. doi: 10.1097/j.pain.0000000000002310. View abstract.
  35. Maghfour J, Rundle CW, Rietcheck HR, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. Dermatol Online J. 2021;27:13030/qt8h50k2vs. View abstract.
  36. Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D. Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. Front Pharmacol. 2021;12:614811. View abstract.
  37. Karoly HC, Mueller RL, Andrade CC, Hutchison KE. THC and CBD effects on alcohol use among alcohol and cannabis co-users. Psychol Addict Behav. 2021. View abstract.
  38. Gaston TE, Ampah SB, Martina Bebin E, et al. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021;117:107862. View abstract.
  39. de Almeida CMO, Brito MMC, Bosaipo NB, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2021. View abstract.
  40. Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System – 2019-2020. Am J Emerg Med. 2021;48:218-223. View abstract.
  41. Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214:370-375. View abstract.
  42. Anderson LL, Doohan PT, Oldfield L, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021. View abstract.
  43. Watkins PB, Church RJ, Li J, Knappertz V. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. Clin Pharmacol Ther. 2020. View abstract.
  44. Thiele EA, Bebin EM, Bhathal H, et al. Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2020. View abstract.
  45. Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel ÂV, Cecilio Hallak JE, Tumas V. A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism Relat Disord. 2021;83:37-40. View abstract.
  46. Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA. Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. J Pharm Pract. 2020:897190020972208. View abstract.
  47. Oruganti P, Betcher S, Wakade Z, Ding X, Abegunde AT. Cannabidiol Oil-Associated Microscopic Colitis. Cureus. 2020;12:e10528. View abstract.
  48. Leehey MA, Liu Y, Hart F, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020;5:326-336. View abstract.
  49. Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2020. View abstract.
  50. Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020; 7:865-874. View abstract.
  51. Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Med Sci Sports Exerc. 2021. View abstract.
  52. Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132:56-61. View abstract.
  53. Woelfl T, Rohleder C, Mueller JK, et al. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020;11:576877. View abstract.
  54. Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020;324:2163-2164. View abstract.
  55. Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324:2177-2186. View abstract.
  56. Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ. Drug-Drug Interactions Between Cannabidiol and Lithium. Child Neurol Open. 2020;7:2329048X20947896. View abstract.
  57. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm. 2020;154:108-115. View abstract.
  58. Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi. J Diet Suppl. 2020;17:599-607. View abstract.
  59. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.Am J Psychiatry. 2018;175:225-231. View abstract.
  60. Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm. 2020;77:1846-1851. View abstract.
  61. Bloomfield MAP, Green SF, Hindocha C, et al. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. J Psychopharmacol. 2020;34:981-989. View abstract.
  62. Lopez HL, Cesareo KR, Raub B, et al. Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects. J Diet Suppl. 2020;17:561-86. View abstracts.
  63. Wang GS, Bourne DWA, Klawitter J, et al. Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. Clin Pharmacokinet. 2020. View abstract.
  64. Taylor L, Crockett J, Tayo B, Checketts D, Sommerville K. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 2020;104(Pt A):106938. View abstract.
  65. McNamara NA, Dang LT, Sturza J, et al. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid. Epilepsia. 2020. View abstract.
  66. Rianprakaisang T, Gerona R, Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clin Toxicol (Phila). 2020;58:215-216. View abstract.
  67. Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:1009-1031. View abstract.
  68. Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77:613-621. View abstract.
  69. Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia. 2020;61:1090-1098. View abstract.
  70. Hobbs JM, Vazquez AR, Remijan ND, et al. Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res. 2020;34:1696-1703. View abstract.
  71. Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. Pediatr Neurol. 2020;105:59-61. View abstract.
  72. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2020;102:106635. View abstract.
  73. Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020. View abstract.
  74. Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61:267-277. View abstract.
  75. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020. View abstract.
  76. Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS Drugs. 2020;34:661-672. View abstract.
  77. Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12:e7688. View abstract.
  78. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95:8268-73. View abstract.
  79. Hacke ACM, Lima D, de Costa F, et al. Probing the antioxidant activity of [delta]-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst. 2019;144:4952-4961. View abstract.
  80. Madden K, Tanco K, Bruera E. Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol. Pediatrics. 2020;e20193256. View abstract.
  81. Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018 Jun;1:65-72.
  82. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2019 Dec 1. View abstract.
  83. de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020 Jan 7:269881119895536. View abstract.
  84. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019 Nov 6;8. pii: E1886. View abstract.
  85. Masataka N. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Front Psychol. 2019 Nov 8;10:2466. View abstract.
  86. Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020 Jan 8. View abstract.
  87. Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. Epilepsy Behav. 2020 Jan;102:106826. View abstract.
  88. Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Front Neurol. 2019 Dec 10;10:1313. View abstract.
  89. “GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance.” GW Pharmaceuticals, 6 April 2020. http://ir.gwpharm.com/node/11356/pdf. Press release.
  90. Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex. Neuropediatrics. 2019. View abstract.
  91. FDA Consumer Updates: What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding. U. S. Food and Drug Administration (FDA). October 2019. Available at: https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
  92. Taylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. J Clin Pharmacol. 2019;59:1110-1119. View abstract.
  93. Szaflarski JP, Hernando K, Bebin EM, et al. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131-136. View abstract.
  94. Pretzsch CM, Voinescu B, Mendez MA, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019:269881119858306. View abstract.
  95. Pretzsch CM, Freyberg J, Voinescu B, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44:1398-1405. View abstract.
  96. Patrician A, Versic-Bratincevic M, Mijacika T, et al. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study. Adv Ther. 2019. View abstract.
  97. Martin RC, Gaston TE, Thompson M, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105-110. View abstract.
  98. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19:2944-2948. View abstract.
  99. Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20. View abstract.
  100. Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects. Molecules. 2019;24. pii: E2967. View abstract.
  101. Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60:e74-e77. View abstract.
  102. Heussler H, Cohen J, Silove N, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019;11:16. View abstract.
  103. Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25:1006-1018. View abstract.
  104. Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019 Aug;60:1586-1592. View abstract.
  105. Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl). 2019;236:2713-2724. View abstract.
  106. Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019. View abstract.
  107. Product information for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
  108. Epidiolex (cannabidiol) prescribing information. Greenwich Biosciences, Inc., Carlsbad, CA, 2019. Available at: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (accessed 5/9/2019)
  109. Statement from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed May 7, 2019).
  110. Agriculture Improvement Act, S. 10113, 115th Cong. or S. 12619, 115th Cong. .
  111. Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order. Fed Regist. 2018 Sep 28;83:48950-3. View abstract.
  112. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018 Nov;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2. View abstract.
  113. Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 Sep;86:131-137. Epub 2018 Jul 11. View abstract.
  114. Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018 Oct;87:131-136. Epub 2018 Aug 9. View abstract.
  115. Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019 Jan-Feb;41:9-14. Epub 2018 Oct 11. View abstract.
  116. Poklis JL, Mulder HA, Peace MR. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int. 2019 Jan;294:e25-e27. Epub 2018 Nov 1. View abstract.
  117. Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019:appiajp201918101191. View abstract.
  118. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391:1085-1096. View abstract.
  119. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378:1888-1897. View abstract.
  120. Pavlovic R, Nenna G, Calvi L, et al. Quality Traits of “Cannabidiol Oils”: Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations. Molecules. 2018 May 20;23. pii: E1230. View abstract.
  121. Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment of Crohn’s Disease, a randomized controlled trial. Dig Dis Sci. 2017 Jun;62:1615-20. View abstract.
  122. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber Syndrome. Pediatr Neurol. 2017 Jun;71:18-23.e2. View abstract.
  123. Yeshurun M, Shpilberg O, Herscovici C, et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study. Biol Blood Marrow Transplant. 2015 Oct;21:1770-5. View abstract.
  124. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015 Aug;56:1246-51. View abstract.
  125. Devinsky O, Marsh E, Friedman D, et la. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15:270-8. View abstract.
  126. 97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39:1777-86. View abstract.
  127. Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017 Jan;32:35-40. View abstract.
  128. Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016 Oct;57:1617-24.View abstract.
  129. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017 Sep;58:1586-92. View abstract.
  130. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376:2011-2020. View abstract.
  131. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA 2017 Nov;318:1708-9. View abstract.
  132. Malfait AM, Gallily R, Sumariwalla PF, et al. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97:9561-6. View abstract.
  133. Formukong EA, Evans AT, Evans FJ. Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L. Inflammation 1988;12:361-71. View abstract.
  134. Valvassori SS, Elias G, de Souza B, et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol 2011;25:274-80. View abstract.
  135. Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151:1272-9. View abstract.
  136. Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View abstract.
  137. Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising new drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65-75. View abstract.
  138. Bisogno T, Di Marzo Y. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Curr Pharm Des 2008;14:2299-3305. View abstract.
  139. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30:271-80. View abstract.
  140. Izzo AA, Borelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515-27. View abstract.
  141. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51:1054-61. View abstract.
  142. Pickens JT. Sedative activity of cannabis in relation to its delta’-trans-tetrahydrocannabinol and cannabidiol content. Br J Pharmacol 1981;72:649-56. View abstract.
  143. Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology (Berl) 1977;55:263-5. View abstract.
  144. Karler R, Turkanis SA. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 1980;68:479-84. View abstract.
  145. Karler R, Cely W, Turkanis SA. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci 1973;13:1527-31. View abstract.
  146. Consroe PF, Wokin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29:500-1. View abstract.
  147. Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201:26-32. View abstract.
  148. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973;25:664-5. View abstract.
  149. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-45. View abstract.
  150. El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010;95:434-42. View abstract.
  151. Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute stress in rats. Br J Pharmacol 2009;156:181-8. View abstract.
  152. Granjeiro EM, Gomes FV, Guimaraes FS, et al. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav 2011;99:743-8. View abstract.
  153. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006;580:4337-45. View abstract.
  154. De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One 2011;6:e28159. View abstract.
  155. Dalton WS, Martz R, Lemberger L, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19:300-9. View abstract.
  156. Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004;75:633-8. View abstract.
  157. Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychomimetic drugs in mice. Eur J Pharmacol 2005;512(2-3):199-205. View abstract.
  158. Long LE, Chesworth R, Huang XF, et al. A behavioral comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13:861-76. View abstract.
  159. Zuardi AW, Rodriguez JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991;104:260-4. View abstract.
  160. Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 2009;93:91-6. View abstract.
  161. Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 2014;24:51-64. View abstract.
  162. Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367:3364-78. View abstract.
  163. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13:421-32. View abstract.
  164. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory effect on marble-burying behavior: involvement of CB1 receptors. Behav Pharmacol 2010;21:353-8. View abstract.
  165. Uribe-Marino A, Francisco A, Castiblanco-Urbina MA, et al. Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2012;37:412-21. View abstract.
  166. Campos AC, Guimaraes FS. Activation of 5HT1A receptors mediates the anxiolytic effects of cannabidiol in a PTSD model. Behav Pharmacol 2009;20:S54.
  167. Resstel LB, Joca SR, Moreira FA, et al. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 2006;172:294-8. View abstract.
  168. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1466-71. View abstract.
  169. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990;253:1002-9. View abstract.
  170. Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100:558-9. View abstract.
  171. Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51:528-34. View abstract.
  172. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56:2115-25. View abstract.
  173. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006;168:235-44. View abstract.
  174. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates high glucose-induces endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007;293:H610-H619. View abstract.
  175. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type 1 diabetic peripheral neuropathic pain. Mol Pain 2010;6:16. View abstract.
  176. Aviello G, Romano B, Borrelli F, et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 2012;90:925-34. View abstract.
  177. Lee CY, Wey SP, Liao MH, et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol 2008;8:732-40. View abstract.
  178. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008;104:1091-100. View abstract.
  179. Valenti M, Massi P, Bolognini D, et al. Cannabidiol, a non-psychoactive cannabinoid compound inhibits human glioma cell migration and invasiveness. 34th National Congress of the Italian Society of Pharmacology 2009.
  180. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90-103. View abstract.
  181. Jacobsson SO, Rongard E, Stridh M, et al. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 2000;60:1807-13. View abstract.
  182. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011;10:1161-72. View abstract.
  183. McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011;129:37-47. View abstract.
  184. McAllister SD, Christian RT, Horowitz MP, et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6:2921-7. View abstract.
  185. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318:1375-87. View abstract.
  186. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a potential anticancer drug. Br J Clin Pharmacol 2013;75:303-12. View abstract.
  187. Schubart CD, Sommer IE, van Gastel WA, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130(1-3):216-21. View abstract.
  188. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19-27. View abstract.
  189. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802. View abstract.
  190. Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:285-95. View abstract.
  191. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18:219-28. View abstract.
  192. Brady CM, DasGupta R, Dalton C, et al. An open-label study of cannabis-based extracts for bladder dysfuntion in advanced multiple sclerosis. Mult Scler 2004;10:425-33. View abstract.
  193. Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16:1349-59. View abstract.
  194. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based treatment in spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45. View abstract.
  195. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity cause by multiple sclerosis. Eur J Neurol 2011;18:1122-31. View abstract.
  196. Overview. GW Pharmaceuticals Web site. Available at: http://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.
  197. Cannabidiol Now Showing Up In Dietary Supplements. Natural Medicines Web site. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Accessed May 31, 2015).
  198. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7(1 Suppl):82-8. View abstract.
  199. Leighty EG, Fentiman AF Jr, Foltz RL. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976;14:13-28. View abstract.
  200. Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16:469-72. View abstract.
  201. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30:277-82. View abstract.
  202. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25:121-30. View abstract.
  203. Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45:1323-31. View abstract.
  204. Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids. Marijuana and Medicine. 1999;91-103.
  205. Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88(15-16):730-6. View abstract.
  206. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39:2049-56. View abstract.
  207. Yamaori S, Maeda C, Yamamoto I, Watanabe K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 2011;29:117-24.
  208. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79:1691-8. View abstract.
  209. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 2009;23:979-83. View abstract.
  210. Morgan CJ, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38:2433-6. View abstract.
  211. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. View abstract.
  212. Leweke FM, Kranaster L, Pahlisch F, et al. The efficacy of cannabidiol in the treatment of schizophrenia – a translational approach. Schizophr Bull 2011;37(Suppl 1):313.
  213. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94. View abstract.
  214. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-50. View abstract.
  215. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36:1219-26. View abstract.
  216. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39:421-9. View abstract.
  217. Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82:1083-92. View abstract.
  218. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana ’90 International Conference on Cannabis and Cannabinoids 1990;2:5.
  219. Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998;40:179-185. View abstract.
  220. Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-185. View abstract.
  221. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View abstract.
  222. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982;76:245-250. View abstract.
  223. Ames, F. R. and Cridland, S. Anticonvulsant effect of cannabidiol. S.Afr.Med.J. 1-4-1986;69:14. View abstract.
  224. Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13:77-83. View abstract.
  225. Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult.Scler. 2010;16:707-714. View abstract.
  226. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol.Res. 2010;32:451-459. View abstract.
  227. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar-Poli, P. Cannabis and anxiety: a critical review of the evidence. Hum.Psychopharmacol. 2009;24:515-523. View abstract.
  228. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem.Behav. 1991;40:701-708. View abstract.
  229. Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav. 1991;40:523-532. View abstract.
  230. Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur.J.Neurol. 2007;14:290-296. View abstract.
  231. Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., and Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol.Life Sci. 2006;63:2057-2066. View abstract.
  232. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39:143-151. View abstract.
  233. Watzl, B., Scuderi, P., and Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991;13:1091-1097. View abstract.
  234. Consroe, P., Kennedy, K., and Schram, K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem.Behav. 1991;40:517-522. View abstract.
  235. Barnes, M. P. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert.Opin.Pharmacother. 2006;7:607-615. View abstract.
  236. Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10:434-441. View abstract.
  237. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89:134-141. View abstract.
  238. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp.Ther. 2004;308:838-845. View abstract.
  239. Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. K., and Filho, Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29:417-426. View abstract.
  240. Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin.Rehabil. 2003;17:21-29. View abstract.
  241. Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed. Washington, DC: American Pharmaceutical Association, 1996.

Natural Medicines disclaims any responsibility related to medical consequences of using any medical product. Effort is made to ensure that the information contained in this monograph is accurate at the time it was published. Consumers and medical professionals who consult this monograph are cautioned that any medical or product related decision is the sole responsibility of the consumer and/or the health care professional. A legal License Agreement sets limitations on downloading, storing, or printing content from this Database. Except for any possible exceptions written into your License Agreement, no reproduction of this monograph or any content from this Database is permitted without written permission from the publisher. Unlawful to download, store, or distribute content from this site.

© 2022 TRC is a registered trademark of Therapeutic Research Center. TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use.

CBD Oil for High Blood Pressure in 2022

Hypertension is a serious condition affecting 33% of US adults above the age of 20. This figure is twice as high for people in their mid-60s and over.

It goes without saying that high blood pressure is becoming a pandemic, which is only going to get worse if people continue to live unhealthy lives full of stress, processed food, and low physical activity.

If you’re reading this, chances are that you, too, have been diagnosed with high blood pressure. The good news is that hypertension doesn’t strike immediately like other serious conditions — so the sooner you act, the better.

While there’s already a large body of scientific research into hypertension, there are no surefire methods that would work for every individual. But thanks to the rise of natural alternatives like CBD oil, many people now assume that cannabis-based products could provide relief from high blood pressure in modern society.

If you’re wondering whether you can use CBD oil for high blood pressure, this article is for you. Below you’ll find my most trusted brands that sell high-quality CBD oil. I’m also going to cover the latest research highlights regarding the effects of CBD on blood pressure.

Best CBD Oils for High Blood Pressure

If you’ve been thinking about CBD oil as your potential hypertension treatment, you’ve probably come across many different brands and products.

The choice may be overwhelming for new consumers, but the key to success is to find a trusted manufacturer that will use organic hemp plants and butane-free extraction methods. The company of your choice should also post lab reports for each product it sells as proof of quality.

All that said, I trust these three brands enough to recommend them for anyone looking for a natural way to improve their quality of life.

1. Royal CBD

Get 15% off all Royal CBD products. Use code “CFAH” at checkout.

  • Royal CBD uses Colorado-grown organic hemp
  • The company makes its products using a supercritical CO2 extraction.
  • They offer both full-spectrum and isolate-based products
  • The oil is very potent — up to 83.3 mg in each mL
  • Every batch of product has been tested for potency and purity in a third-party laboratory
  • No vape oils available yet
  • These products are more expensive than other brands, but that’s justified by the quality of ingredients
My Thoughts on Royal CBD:

Launched in 2018 by a group of cannabis aficionados, Royal CBD is a premium manufacturer of hemp-derived CBD products. The company’s philosophy revolves around simplicity and the quality of ingredients. Their CBD oil is sourced from organic hemp grown by American farmers who prefer to cultivate their crops without pesticides and chemical fertilizers.

Royal CBD offers CBD in its most common forms, including sublingual drops, capsules, and edibles. All of their products are extracted using pressurized CO2, a technique that yields clean and potent extracts.

The Royal CBD oil comes in three different strengths:

It’s a full-spectrum extract, so you get CBD along with other cannabinoids and terpenes naturally occurring in hemp. Experts believe full-spectrum extracts to be more effective in certain conditions when compared to isolated CBD.

Royal CBD regularly tests its products in a 3rd-party laboratory for their cannabinoid profiles and to make sure they are free of contaminants.

If you dislike the taste of natural CBD oil, you may want to try Royal CBD capsules. These are quite potent, too, as each softgel carries 25 mg.

2. Gold Bee (Best Organic CBD Oil)

Pros:
  • Unique product selection
  • Gold Bee uses non-GMO, Colorado-grown hemp
  • The oil contains full-spectrum CBD
  • The company’s products are extracted with CO2
  • You’re getting up tp to 1200 mg of CBD per bottle
  • The oil is sweetened with organic honey
  • Third-party lab tested for potency and purity
Cons:
  • No high-strength oils
  • Not available in-store
What I Like About Gold Bee:

Gold Bee was launched in 2019 in California by a group of cannabis enthusiasts who earlier operated on the superfoods market. Gold Bee offers an unusual product line up, including full-spectrum honey-sweetened CBD oil and CBD-infused honey sticks and gummies. All Gold Bee’s products are made from organic hemp and tested for potency and purity in a third-party laboratory.

I couldn’t help but try the 1200 mg kiwi-flavored CBD oil as I was curious about the taste of full-spectrum CBD that is sweetened with organic honey. The flavor was spot-on, but what surprised me the most was the very calming effect it had on my body. This was unusual for me because I’ve tried some higher-potency oils in my life and the stress-relieving effects weren’t as good as with this brand.

If you’re looking for a risk-free way to check out Gold Bee’s products, you can use its 30-day money-back guarantee and get a full refund for your order if you’re not satisfied with the results.

3. CBDPure

  • CBDPure makes full-spectrum CBD oil
  • The company uses CO2 for extraction
  • All products are sent to a 3rd-party laboratory for a content analysis
  • You can send your order back for a full refund within 90 days as part of CBDPure’s 100% Satisfaction Guaranteed program
  • Narrow product selection
  • Lower potency than Royal CBD
My Thoughts on CBDPure:

One thing I particularly appreciate about CBDPure is the company’s transparency. CBDPure openly shares every detail of their activity, from sourcing to packaging. They also provide a Certificate of Analysis for each batch of their oils and capsules.

CBDPure has a modest product selection, offering only full-spectrum oil drops and softgel capsules. The oil is less potent than other brands in this ranking, but the company sells it in larger bottles, so if you benefit from low doses, you may get supplied for a couple of months.

For stronger effects, you may try CBDPure’s softgels which carry 25 mg of CBD per capsule. And, if you end up unsatisfied with your product, you can send the order back within 90 days and receive a full refund.

4. CBDistillery

  • CBDistillery uses locally grown hemp
  • The company’s products are available as full-spectrum or isolate
  • Impressive product selection
  • Each batch is tested in a 3rd-party lab for potency and purity
  • CBDistillery is one of the most affordable brands on the market
  • The hemp used by CBDistillery isn’t organic
  • The CBD oil is available only in the unflavored option
My Thoughts on CBDistillery:

CBDistillery is one of the industry’s trailblazers. This company has been offering high-quality CBD oil products for over 5 years now on top of providing education for its customers under the #CBDMOVEMENT hashtag.

CBDistillery has plenty of different CBD products in its collection, from sublingual drops to capsules, topicals, gummies, and vapes. The company’s CBD oil comes as full-spectrum or CBD isolate.

These oils are available in two different sizes — 15 mL and 30 mL. The potency of the 15 mL bottle ranges between 150–1,000 mg of CBD, whereas the 30 mL bottle offers 2,500–5,000 mg.

With such a broad potency range, CBDistillery oil is good for both new consumers and seasoned users alike. The only disadvantage of the company’s product lineup is that they’re not made with organic hemp.

However, once you consider the price of CBDistillery products, you’ll understand why I’ve decided to choose this brand as my third favorite. CBDistillery might not sell the best CBD oil on the market, but they definitely offer the best CBD oil in this price range.

What Is High Blood Pressure (aka Hypertension)?

Blood pressure is measured by the amount of pressure applied by blood flow onto the internal system of arteries in the human body.

This pressure tends to go up and down throughout the day as your body reacts to environmental, physical, and emotional stimuli.

Although the changes in blood pressure can be frequent, there’s a specific range the pressure needs to stay within in order to maintain optimal health.

The Centers for Disease Control (CDC) reports that about one-third of American adults have blood pressure that consistently exceeds the normal range. This condition of consistently high blood pressure is known as hypertension — it can have a series of negative consequences on your health.

Hypertension is the most common cause of cardiovascular disease. As noted by the CDC, high blood pressure was responsible for 410,000 deaths in 2014 alone. In addition, hypertension and its collateral damage are estimated to cost Americans up to $50 billion each year.

What Are the Symptoms of High Blood Pressure?

How do you know if you have hypertension?

The problem with this condition is that it may not give you as many negative symptoms as other diseases, so sometimes, it may be extremely difficult to diagnose hypertension at home.

If you want to prevent hypertension or detect it in its infancy, you should always schedule regular appointments with your physician to monitor blood pressure.

The symptoms below indicate that you need to make an appointment at your local medical center as soon as possible:

  • Frequent, severe headaches
  • Permanent fatigue
  • Problems with vision
  • Changes in heartbeat

How Is Hypertension Treated?

As with any chronic condition, pharmaceuticals are the treatment of choice for most people. As much as I agree that they pull blood pressure numbers back into the normal range, I’m not a fan of prescription or OTC medications because these come with their own set of side-effects.

Some of them may even worsen your condition because they can cause muscle weakness, fatigue, lightheadedness, and electrolyte deficiencies.

As a matter of fact, one of the most important measures you can take to lower blood pressure is to reach the cause of your hypertension. You need to incorporate some radical lifestyle changes. Diet, exercise, and stress management can contribute to lower blood pressure and, at the same time, prevent the side effects of hypertension.

These changes, require time and commitment to receive any benefits.

How Could CBD Lower Blood Pressure?

Research shows that supplementation with CBD may be effective in reducing blood pressure in healthy adults, thus decrease the risk of atrial fibrillation. CBD may also mitigate negative changes in the pressure caused by various triggers.

This may mean a lot for hypertension patients who are in search of alternative ways to manage their symptoms and bring their blood pressure back to the normal range.

There haven’t been many trials that would test the effectiveness of CBD in chronic hypertension, so while the current findings are promising, CBD still isn’t an approved form of hypertension treatment.

Scientific Research on CBD and Blood Pressure

If you’re interested in using CBD oil for high blood pressure, read on to explore the latest scientific findings.

1. CBD May Inhibit Stress-Induced Blood Pressure Changes

In a 2019 study, Brazilian researchers investigated the effects of several different CBD doses on anxiety levels caused by public speaking.

They tested the following dosages:

Anxiety can be measured with telltale signs such as increased heart rate and blood pressure. The data from this study showed that the medium dose of CBD produced a notably improved stress response to giving a speech, giving us an indirect look at the effects of CBD on blood pressure.

The study can also serve as a reference point for drafting out dosage guidelines for CBD oil and hypertension.

2. CBD Acts as a Vasodilator

As noted in a 2017 randomized crossover study, a single dose of cannabidiol reduced blood pressure in healthy subjects, specifically in male adults.

Starting from their regular blood pressure range, the participants were asked to engage with two different types of stressors — exercise and cold. These stressors are known to cause a vivid increase in blood pressure.

While the subjects who took CBD prior to exposure to these stressors still experienced a rise in blood pressure, it was much lower than that shown by the placebo group.

The researchers concluded that CBD may be an effective compound in stress management by lessening the body’s reaction to various stressors and thus potentially reducing the risk of side effects caused by hypertension.

3. CBD May Lower Heart Rate

In a 2009 study, rats were put under a stressful situation that caused their blood pressure and heart rate to increase. A single dose of CBD lowered both their blood pressure and heart rate. While more human research is needed to make conclusive claims, CBD may have the potential to lower heart rate under stress.

However, a 2017 review of 25 studies found that there’s no link between CBD and reduced heart rate under non-stressful conditions.

Potential Risks of Using CBD Oil for High Blood Pressure

While the early findings on the effects of CBD for high blood pressure are optimistic, people who already use certain medications for hypertension should absolutely consult with their doctor before buying any CBD product.

That’s because CBD oil can interact with these medications and cause blood pressure to drop too low — and too low isn’t good either.

People using CBD oil derived from marijuana may experience an acute, dose-dependent increase in blood pressure and heart rate shortly after consumption, but that’s caused by the THC in those products.

The increase in blood pressure and heart rate is then followed by a modest hypotensive effect — a decrease in blood pressure.

Hemp-derived CBD oil usually has less than 0.3% and thus can’t induce such effects. Other than the aforementioned drug interactions, CBD oil comes with a few mild side effects such as the dry mouth and appetite suppression.

What’s the Best CBD Oil Dosage for High Blood Pressure?

If you’re looking for a one-size-fits-all dosage, you’ll be deeply disappointed because dosing CBD depends on many different factors.

The list includes your age, weight, metabolism, prior experience with CBD, and the severity of your symptoms.

Experts recommend starting with 1–6 mg of CBD for every 10 pounds of body weight. If you’ve never taken CBD before, it’s best to start at the lowest point and slowly work your way up to the effective dosage.

Depending on the route of administration, it may take anywhere from 5 to 90 minutes for the effects to take hold.

Summarizing the Potential Effects of CBD Oil on Blood Pressure

Statistics are merciless for modern society when it comes to hypertension. The fact that we’re always rushing from A to B, spend the majority of our time sitting in one place, and consume too much processed food results in more people developing hypertension each year.

Aside from introducing obvious changes to your lifestyles, such as eating nutritious food, exercising a lot, and abstaining from alcohol and cigarettes, you may incorporate CBD oil into your regime for a significant improvement in your quality of life.

The latest research indicates that CBD is capable of lowering blood pressure on a few different levels, although more studies are needed to make conclusive claims in this subject. If you’re considering taking CBD oil for high blood pressure, make sure to talk about it with your doctor to determine if CBD products are right for you.

Do you use CBD oil for high blood pressure?

References:

  1. Linares, I.M., Zuardi, A.W., Pereira, L.C., Queiroz, R.H., Guimaraes, F.S. & Crippa, J.A. (2019). Cannabidiol Presents an Inverted U-shaped Dose-response Curve in a Stimulated Public Speaking Test. Brazilian Journal of Psychiatry, 41(1).
  2. Jadoon, K.A., Tan, G.D., & O’Sullivan, S.E. (2017). A Single Dose of Cannabidiol Reduces Blood Pressure in Healthy Volunteers in a Randomized Crossover Study. Research Scholars Program in Hematology/Oncology, 2(12).
  3. Stanley, C.P., Hind, W.H., O’Sullivan S.E. (2012). Is the Cardiovascular System a Therapeutic Target for Cannabidiol? British Journal of Clinical Pharmacology, 75(2).
Nina Julia

Nina created CFAH.org following the birth of her second child. She was a science and math teacher for 6 years prior to becoming a parent — teaching in schools in White Plains, New York and later in Paterson, New Jersey.

Leave a comment Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

CBD Oil for High Blood Pressure (Hypertension) – June 2022

A sublingual application of CBD oil tincture may be the best way to take CBD for high blood pressure as it gets absorbed by the body fast, and the effects are felt for an extended period.

Why People Are Taking CBD for High Blood Pressure

According to the Centers for Disease Control and Prevention (CDC), high blood pressure can harden and narrow the arteries, which decreases the flow of blood and oxygen to the heart, leading to heart disease (5 ) .

In a 2015 study conducted by researchers from the University of Nottingham Royal Derby Hospital in the UK, CBD was shown to be a potent vascular relaxant to human gut arteries, suggesting its potential benefits to dilate blood vessels and increase blood flow (6 ) .

How CBD Oil Works to Help with High Blood Pressure

CBD has been shown to possess potential benefits that may help lower blood pressure by addressing health issues that cause blood pressure to rise.

CBD’s Anti-Anxiety Effects

Some factors linked to high blood pressure are anxiety and lack of sleep.

In a 2019 study published in The Permanente Journal , sleep and anxiety scores were measured in human subjects, and the findings showed that CBD could hold benefits for anxiety-related disorders (7 ) .

In another study , which was published in the Journal of Alternative and Complementary Medicine in 2019, CBD was shown to help in the treatment of post-traumatic stress disorder (PTSD) (8 ) .

The relaxation response can reduce blood pressure in people with hypertension, as indicated in the results of a study published in the Journal of Alternative and Complementary Medicine in 2018 (9 ) .

CBD as a Vasodilator

As a natural vasodilator, CBD may help improve positive cardiovascular health by widening the blood vessels to allow smooth blood flow.

CBD’s role as a vasodilator was highlighted in a double-blind, placebo-controlled, and randomized crossover study conducted by researchers from the Royal Derby Hospital Centre and Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital in the UK in 2017 (10 ) .

In the said study , researchers explored the connection between CBD and a reduction in blood pressure, and they found that a single dose of CBD oil significantly lowered blood pressure in a small study of healthy human volunteers, both under stress and at rest.

However, the authors also noted that “there are no dedicated studies in humans to date, to our knowledge, looking at the effect of CBD on either resting cardiovascular measurement or on the responses to stress, with continuous monitoring of cardiovascular parameters.”

CBD’s Anti-Inflammatory Effects

Studies conducted by researchers from the University of South Carolina School of Medicine in 2009 also reveal that CBD possesses anti-inflammatory properties. Since inflammation can cause high blood pressure or vice versa, eliminating inflammation may help alleviate high blood pressure (11 ) .

However, inflammation may be a result of other diseases as well. Thus, leading a healthy lifestyle while using CBD oil is advised.

CBD vs. Cortisol Secretion

Cortisol, the “stress hormone,” is released by the body under stress. An elevated cortisol level may cause a physical stress response in the body that could raise blood pressure.

Results from a 1993 study published in the Brazilian Journal of Medical and Biological Research suggested that CBD interferes with cortisol secretion (12 ) . Thus, if high blood pressure is due to elevated stress levels, CBD oil may theoretically be beneficial.

CBD and The Dynamics of Blood Flow

In a systematic review and meta-analysis published in the Frontiers in Pharmacology Journal in 2017, the authors examined the hemodynamic (blood flow) effects of CBD (13 ) .

The authors of the said study concluded that CBD might be used as a potential remedy for cardiovascular disorders, such as hypertension and stroke.

However, they found no evidence that CBD provides similar results under non-stressful conditions.

Much of these data were from mice, and results from human studies on the effects of CBD on hemodynamics is still limited.

CBD Interacts with Neurotransmitters

Results of a 2017 study published in the Cannabis and Cannabinoid Research Journal show how a neurotransmitter, such as anandamide, plays a critical role in the functioning of the heart (14 ) .

Data from the study has shown that CBD oil regulates the reuptake of essential heart neurotransmitters that control the cardiovascular system.

CBD’s Neuroprotective Effects

A study published in the British Journal of Clinical Pharmacology in 2013 has shown how CBD allows blood flow in the vessels to maintain healthy blood pressur e in animal models (15 ) .

The review has also presented evidence of the positive effects of CBD in the cardiovascular system.

Data from the said study illustrate that CBD potentially provides neuroprotective effects, which may help protect the brain against stroke.

The findings also suggest that CBD can induce a healthy heart rhythm after an ischemic attack, which is caused by a build-up or blockage in the arteries. Thus, CBD was shown to potentially improve heart performance immediately after a heart attack in non-human models.

Although the results demonstrate that the cardiovascular system is a valid therapeutic target for CBD, the target sites of action for CBD remain to be established for most of the responses.

As more and more studies and clinical trials are conducted in human subjects, CBD oil’s efficacy in treating high blood pressure would become more explicit.

The Pros and Cons of CBD Oil for High Blood Pressure

The Pros
  • CBD “is generally well tolerated with a good safety profile,” as the World Health Organization (WHO) states in a critical review (16 ) .
  • CBD’s feasibility as a potential remedy to hypertension-related symptoms has been shown in the numerous studies stated above.
The Cons
  • Studies are too limited to determine whether or not CBD is an effective treatment for conditions other than the ones approved by the U.S. Food and Drug Administration (FDA).
  • As with the use of any natural chemical compound, there are risks involved in using CBD. According to the Mayo Clinic, possible side effects include drowsiness, dry mouth, diarrhea, fatigue, and reduced appetite (17 ) .
  • Most of the results from blood pressure-related studies done on CBD have been gathered through tests that involve healthy volunteers, very low population sizes, or animals, like that of a study done on rats (18 ) .
  • CBD has been shown to alter how the body metabolizes certain medications, as a 2017 research reveals (19 ) . With results published in the Cannabis and Cannabinoid Research Journal , the research suggests that the combination of CBD with other high blood pressure medications has the potential to alter the blood concentrations of either substance.

Results of a study published in the Medicines Journal indicated that the CYP450 family of enzymes is responsible for metabolizing several phytocannabinoids (cannabinoids that exist naturally in the cannabis plant), including CBD (20 ) .

  • The lack of regulation makes it difficult to determine whether the CBD gummies, tinctures, patches, balms, and gelcaps contain what the product label claims.

A 2017 review published in the Journal of the American Medical Association revealed labeling inaccuracies among CBD products. Some products had less CBD than stated, while others had more (21 ) .

Experts recommend speaking with a physician before adding CBD onto the medications that are currently taken. The doctor may want to reduce the dosage strength of the blood pressure prescription before incorporating CBD oil into the daily regimen of an individual.

How CBD Oil Compares to Alternative Treatments for High Blood Pressure

Although the prescription medications currently available for hypertension are effective, they bring about side effects, which can make the treatment an unpleasant experience.

Cannabidiol (CBD), on the other hand, is a natural alternative that has shown to have little side effects, and the side effects of CBD are less common than the effects associated with most pharmaceutical medications used to treat high blood pressure.

How To Choose The Right CBD for High Blood Pressure

The best CBD oil product to use for high blood pressure is CBD tincture. By taking a sublingual dosage, the optimum level of CBD gets absorbed into the system, which means CBD works the fastest, and the effects are probably felt the longest.

However, regardless of the form of CBD product one chooses, he or she must employ careful consideration in choosing the best CBD oil for high blood pressure that is right for him or her.

  1. Research on the exact legal stipulations applicable to CBD in the area where it would be purchased and used.
  2. Purchase only from legitimate and reliable big brands. The majority of companies that manufacture the best CBD oil products grow their hemp from their farm, or they purchase from licensed hemp producers.
  3. When buying from an online store, do some research on product reviews first. When buying from a physical store or dispensary, check whether the store is authorized by the government to sell CBD.
  4. One important thing to look for in CBD products is certification codes. Several certification authorities approve certain products only after some thorough screening tests.
  5. Compare company claims about their products’ potency with that of the third-party lab reports.
  6. Consulting with a trusted medical professional who is experienced in CBD use is ideal before purchasing any CBD product .

CBD Dosage For High Blood Pressure

In a 2019 review, Mayo Clinic suggests CBD dosages based on publications, scientific research, traditional use, and expert opinion (22 ) .

The doses and duration of treatment depend primarily on the illness. However, there is no specific dose recommended for high blood pressure.

Results of a 2017 study published in the Cannabis and Cannabinoid Research Journal provided evidence that a dosage of up to 1,500 mg of CBD a day is well-tolerated by humans (23 ) .

The authors of the study also found that at lower doses, CBD showed physiological effects that could potentially help promote and maintain health, including antioxidative, anti-inflammatory, and neuroprotection effects.

Following the dosing instructions on the CBD product of choice and starting with a low dose are the best course of action for those who would like to try CBD. Taking high doses at the beginning may bring about adverse reactions in the user.

As with any medication, the dose would depend on the metabolism, genetics, size, and body weight of a person.

How to Take CBD Oil for High Blood Pressure

There are various ways to consume CBD oil, and the delivery format would most likely depend on personal preferences and lifestyle.

CBD Oil Capsules and Edibles

CBD oil capsules and edibles, such as brownies, gummies, and lozenges, are a convenient and straightforward way to take CBD oil, especially for beginners.

This format is easy to work into a routine, and the dose is consistent. Depending on the metabolism of an individual, the effects can last between 6 and 12 hours. Thus, one dose is probably all that is needed during the day.

However, consuming CBD oil can delay its effects as it has to pass through the digestive system before it gets absorbed into the bloodstream. Given that the effects of the CBD oil could take at least 20 minutes to an hour to appear, CBD oil capsules and edibles do not provide immediate relief.

CBD Oil Tinctures or Drops

CBD oil tinctures or drops are a practical option for those who seek faster results and maximum dosage control.

Tinctures and drops are administered under the tongue, through which the CBD oil is absorbed directly into the bloodstream.

Place the desired quantity of drops under the tongue using a dropper, and then let the CBD oil stay in place for at least 60 seconds. Once 60 seconds have passed, swallow the CBD oil.

Sublingual application allows for results to be experienced within 30 to 60 minutes after its use, and the effects can be felt for 4 to 6 hours.

Since tinctures and drops are convenient and easy to store and travel with, they can be effortlessly administered when needed.

However, one significant drawback to CBD oil tinctures and drops is the taste, as not everyone appreciates the natural, earthy, and sometimes bitter flavor of hemp.

Although some products come in various flavors to compensate for the unpleasant taste, the addition of sugar and chemicals may be something that one wants to avoid.

CBD Oil Vapes

CBD oil vapes are one of the accelerated ways to get CBD into the body since it enters the bloodstream through the lungs, without going through the digestive system.

When vaping CBD oil, effects can be felt in minutes. However, the effects last only for 30 minutes to an hour or two.

Also, with vaping, it is difficult to determine precisely how much CBD is in each draw. Although labels for CBD oil vape products usually indicate the amount per inhale, the amount may vary in individuals. Thus, getting the dose right requires a bit of experimentation at first.

Understanding High Blood Pressure

Blood pressure is influenced by how much blood the heart pumps, how hard it pumps, and the resistance to blood flow in the arteries.

According to Mayo Clinic, the higher the amount of blood the heart pumps and the narrower the arteries, the higher the blood pressure (24 ) .

The narrowing and blocking of blood vessels that is caused by high blood pressure, or hypertension, affects heart health by increasing the risk of developing heart failure.

What A Blood Pressure Reading Means

When the doctor measures blood pressure, the reading is given in two numbers. The first number, referred to as systolic blood pressure, is the pressure caused by the heart contracting and releasing blood. The second number, called diastolic blood pressure, is the pressure when the heart relaxes and fills with blood.

The blood pressure reading is given as the systolic blood pressure number over the diastolic blood pressure number, such as 135/70.

A normal blood pressure reading for adults is 120/80, according to the American Heart Association (AHA) (25 ) .

Are There High Blood Pressure Symptoms?

The American Heart Association (AHA) calls high blood pressure a “silent killer.” An individual can have high blood pressure for years without any indications (26 ) .

Most people with high blood pressure do not exhibit symptoms, even though blood pressure readings rise to critically-high levels.

Meanwhile, AHA says, some people with high blood pressure may experience shortness of breath, headaches, or nosebleeds. However, these symptoms are not specific and do not occur until high blood pressure has reached a life-threatening stage.

Still, even in the absence of symptoms, damage to the heart and blood vessels continues and can be detected, AHA says .

The agency warns that undetected or unregulated high blood pressure intensifies the risk of severe health problems, including strokes and heart attacks (27 ) .

High blood pressure typically develops over several years, and it eventually affects almost everyone (28 ) .

The National Institute on Aging (NIA) states that high blood pressure is a critical health issue that is typical among older people (29 ) .

Fortunately, it is not difficult to detect high blood pressure. One can work with a doctor to control the condition once diagnosed.

To learn more about the studies on blood pressure, go to ClinicalTrials.gov or PubMed.gov (30 ) .

Traditional Medications for High Blood Pressure

  • Diuretics, like Diuril and Lozol, increase urination which reduces sodium and fluid in the body. Because diuretics lower blood volume, they help lower blood pressure. However, one side effect of diuretics can be a loss of potassium, which is needed for proper muscular movement.
  • Angiotensin II receptor blockers (ARBs) like Diovan, which, as vasodilators, dilate blood vessels. Their potential side effects include skin rashes, swelling mouth, joint and back pain, flu-like symptoms, nausea, headaches, and diarrhea.
  • Metoprolol beta-blockers, like Toprol-XL and Lopressor, slow the heart rate. However, they can cause diarrhea, constipation, vomiting, fatigue, anxiety, depression, insomnia, shortness of breath, and decreased libido.
  • Angiotensin-converting enzyme (ACE) inhibitors like Vasoctec and Benazepril prevent the contraction of blood vessels. Some adverse side effects may include skin rash, swelling mouth, dry cough, headaches, dizziness, and diarrhea.

According to an article published in MedlinePlus by the U.S. National Library of Medicine, high blood pressure medicines may cause some common side effects, such as diarrhea or constipation, dizziness, erection problems, fatigue, nausea or vomiting, skin rash, and weight loss or gain without trying (32 ) .

Sometimes, a person may need to take more than one type of drug to manage blood pressure.

Although a single drug would often be used initially, two drugs could be started for stage 2 high blood pressure.

The AHA describes stage 2 hypertension as the stage when blood pressure consistently ranges at 140/90 mm Hg or higher (33 ) .

People taking medications for hypertension are also warned that mixing beta-blockers and angiotensin II receptor antagonists must only be done at the recommendation of a physician since the combination can lead to acute renal failure, as a 2013 study published in the Hypertension Research Journal suggests (34 ) .

Lifestyle Changes to Help Prevent High Blood Pressure

  • Eating a healthy diet that is low in fat, cholesterol, and salt to prevent further plaque build-up in the arteries.
  • Exercising regularly to strengthen your heart. This activity could be something as simple as taking a 30-minute walk each day.
  • Engaging in activities that help manage stress, such as meditation, journaling, making art, and seeing a therapist.

What to Know About CBD Oil

CBD oil contains CBD , or cannabidiol , as its primary active ingredient. Cannabidiol is associated with the previously mentioned benefits, including controlling blood pressure.

Comparing CBD and THC

CBD comes from cannabis and is naturally found in hemp plants. CBD is one of more than 100 cannabinoids that occur naturally within the plant. This compound is also commonly used to produce CBD hemp oil supplements.

Hemp seed oil is produced by extracting the oil from the seeds of the hemp plant itself. This oil is abundant in nutrients, such as omega-3 and omega-6 fatty acids, making it ideal for digestion. Although some people refer to “hemp extract” as hemp oil, the term “hemp oil” is synonymous with the term “hemp seed oil.”

Chemical compounds in cannabis, called cannabinoids, have shown various potential benefits by activating the body’s endocannabinoid system (ECS), which is involved in regulating a variety of functions including sleep, appetite, pain and immune system response (36 ) .

The body produces endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors in the nervous system.

The medicinal efficacy of cannabis can be optimized by incorporating the various cannabinoids, flavonoids, and terpenes that are intrinsic components of cannabis plants.

CBD is non-psychoactive, contrasting with THC (tetrahydrocannabinol), another primary cannabinoid. THC is the most significant factor contributing to the high associated with using cannabis.

Consuming CBD without any THC does not produce those effects, which means that nearly everyone should be able to function as they usually do when taking CBD.

The lack of high allows users to continue with work, school, and other commitments without a decrease in performance. It also makes CBD oil safe to take , even for those who must pass regular or random drug tests.

CBD oil must not contain any THC for CBD to be non-psychoactive. Products containing CBD isolates do not have THC, while full-spectrum CBD products do.

Any product that one buys should also state the percentage of THC, information which one can also get from its certificate of analysis.

Other Health Benefits of CBD Oil

Here are some of the more critical benefits associated with cannabidiol .

Treating Seizures

CBD can help treat some of the worst types of seizure disorders that exist, including Lennox-Gastaut syndrome and Dravet syndrome, both of which affect children and do not typically respond to traditional medications for treating seizures (37 ) .

Even the U.S. Food and Drug Administration (FDA) recognizes the ability of CBD to treat seizure disorders (38 ) . The first cannabis-derived medication it approved is Epidiolex, which treats these conditions. That medication contains CBD.

Treating Anxiety Disorders and Depression

Those who suffer from anxiety may experience relief with CBD. Results from a 2019 study published in the Brazilian Journal of Psychiatry showed CBD’s anxiolytic effect on public speaking, and there is plenty of anecdotal evidence (39 ) .

In another study , which was published in the Journal of the American College of Cardiology , CBD was shown to attenuate oxidative stress, as well as cardiac dysfunction, fibrosis, and cell death in a mouse model (40 ) .

Treating Pain

One of the most popular uses of CBD oil is its ability to reduce chronic pain . Animal studies, like the study published in the European Journal of Pain in 2016, show that topically applied CBD may theoretically help provide pain relief and reduce inflammation from arthritis (41 ) .

In another study published in the Journal of Experimental Medicine , CBD was shown to reduce neuropathic pain (42 ) . This finding is crucial as it is one of the hardest types of pain to treat.

Some countries approve oral sprays like Sativex, which contains both CBD and THC (43 ) . This spray effectively treats the pain associated with multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord (central nervous system).

However, as Sativex and certain medications may trigger a drug interaction, experts advise consulting with a doctor first about all the prescription, over-the-counter (non-prescription), and herbal medications that are being taken before starting to use Sativex oral spray.

Protecting the Brain

CBD research , conducted on animal models and humans and published in the Surgical Neurology International in 2018, has shown numerous therapeutic properties for brain function and protection, both by its effect on the endocannabinoid system directly and by influencing endogenous cannabinoids (44 ) .

Researchers in a study published in the Journal of Psychopharmacology noted a possible effect of CBD in improving the quality of life in patients with Parkinson’s disease without adverse outcomes (45 ) .

Studies analyzed in a 2017 review conducted by experts from the Western Sydney University in Australia also provided proof of principle for the therapeutic benefits that CBD and possibly CBD-THC combinations may provide (46 ) .

Data suggest that these combinations may help with the therapy of Alzheimer’s disease (named after Dr. Alois Alzheimer, who noted the symptoms in 1906).

May Help Fight Cancer

A 2010 study published by the American Association for Cancer Research showed a CBD-induced cell death of breast cancer cells, suggesting that the use of CBD oil may also suppress tumor growth (47 ) .

Research on cannabinoids published in the Future Medicinal Chemistry demonstrates that cannabinoids may also prove beneficial in certain types of cancers that are activated by chronic inflammation (48 ) .

In such instances, cannabinoids, as anti-inflammatory agents, can either directly prevent tumor growth or suppress inflammation .

Meanwhile, in-depth research on CBD yields mixed results.

In a recent study published in the Bosnian Journal of Basic Medical Sciences , researchers recognized the antitumor effects of cannabinoids in various cancer types (49 ) .

However, these antitumor effects of cannabinoids have to prevail over their known immunosuppressive effects, which can potentially promote the production or formation of tumors.

Recent studies are still limited when it comes to CBD and cancer prevention. Longitudinal studies of humans using specific CBD products, controlling for frequency of use and dosing are needed.

Overcoming Substance Abuse

There is some evidence that using CBD may help those with addiction overcome their substance abuse.

Published in the Journal of Substance Abuse Treatment , results from a 2015 study conducted on animal models showed CBD reduced heroin-seeking behavior and reduced morphine dependence (50 ) .

The Legality of CBD Oil

The Cannabis sativa plant produces both hemp and marijuana. The difference between the two plants is the percentage of THC that they contain.

A cannabis plant that has 0.3 percent or less of THC content classifies as hemp, while a cannabis plant containing over 0.3 percent of THC is considered marijuana.

In the United States, cannabis-related laws are continually changing. Since marijuana and THC are on the list of controlled substances, they are currently prohibited under federal law (51 ) .

Meanwhile, confusion arises due to regulations that vary depending on whether the CBD is hemp-derived or extracted from marijuana. The former is legal at the federal level, while the latter is not.

Many states and Washington, D.C. have passed cannabis-related laws, making medical marijuana with high levels of THC legal. Still, marijuana may require a prescription from a licensed physician (52 ) .

Also, several states have made recreational use of marijuana and THC legal. One should be able to buy CBD in states where marijuana is legal for recreational or medical purposes.

NORML has information regarding state laws and penalties. (53 ) .

Individuals who possess cannabis-related products in a state where they are illegal or do not have a medical prescription in states where the products are legal for medical treatment could face legal penalties.

For a complete list of legal medical marijuana states and D.C., including the corresponding laws, fees, and possession limits, visit ProCon.org (54 ) .

Conclusion

According to the Centers for Disease Control and Prevention (CDC), about 75 million American adults, or 1 in 3 adults, have high blood pressure (55 ) . People with high blood pressure have a greater risk of heart disease and stroke, the leading causes of death in the United States.

CBD oil has shown to be a natural remedy to issues that could be linked to high blood pressure, such as stress and p a in (56) .

Meanwhile, using medications as prescribed and making lifestyle changes can enhance the quality of life and reduce the risk of hypertension, says the American Heart Association (AHA) (57 ) .

Still, before experimenting with different CBD products and dosages, speak to a doctor about a CBD treatment or using CBD oil for treating high blood pressure.

For anyone still looking for more information on CBD as a medical supplement, speaking with a cannabis doctor who specializes in the subject is the best course of action.